Purpose The main aim of this study was to detect the presence of JAK2 mutation and its assessment in relation to the clinical, hematological, and mutational profile of young patients with established polycythemia.

Methods Cross-sectional observational study was undertaken over a period of 1 year in a tertiary care center. Sixty patients were included in our study between the age 18 and 50 years with confirmed diagnosis of polycythemia vera. Reports of all the investigations including bone marrow biopsy and JAK2 mutation testing were assessed.

Results Presence of JAK2 mutation V617F was found in 38% patients, while bone marrow panmyelosis was present in 67% patients. Higher mean hemoglobin levels were observed in JAK2 mutation-positive patients, compared with those who were negative. Thrombosis-related complications were observed in five patients, all of whom were JAK2 mutation positive, while out of the 18 patients requiring phlebotomy, 15 patients were JAK2 mutation positive.

Conclusion JAK2 mutation V617F in young Indian population is seen in significantly less cases as compared with Western data, while bone marrow panmyelosis is frequently observed and thus a significant finding for diagnosing polycythemia in our setting. Median hemoglobin was greater for JAK2 mutation-positive cases and so were the phlebotomy requirements and thrombotic events occurrences. Forty-two percent patients had history of some exposure to high-altitude areas adhering to the fact that high altitude is an established risk factor for developing polycythemia and the same is reinforced by our study.

Available if required.

All authors provided significant contribution in the form of data collection, analysis and gave necessary inputs for the designing of the manuscript.

The study was conducted after obtaining ethical clearance from institutional ethical committee. Written informed consent from the patients was taken before data collection was done.

Article published online:
11 July 2022

© 2022. Spring Hope Cancer Foundation & Young Oncologist Group of Asia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India